IFNAR2 and COVID-19: The summary databased Mendelian randomization (SMR) method identified rs2252639 of IFNAR2 associated (p < 1 × 10−4) with severe COVID-19 and an association with COVID-19 hospitalization (p < 1 × 10−6); the authors assume that IFNAR2 is involved in determining COVID-19 severity and could be a potential therapeutic target for the treatment of COVID-19 [30].